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Abstract
Skeletal muscle atrophy can result from a range of physiological conditions, including denervation,
immobilization, hindlimb unweighting, and aging. To better characterize the molecular genetic
events of atrophy, a microarray was performed using skeletal muscle isolated from mice after 3
and 14 days of denervation and compared to control muscle to identify novel atrophy-induced
genes. The microarray revealed that FGGY carbohydrate kinase domain containing (Fggy) is
expressed in skeletal muscle and is induced in response to denervation. Bioinformatic analysis of
the Fggy gene locus revealed two validated alternative isoforms, that we have termed Fggy-L-552
and Fggy-S-387, which have distinct transcription initiation sites. In order to confirm that Fggy is
expressed in muscle, the cDNAs of the two validated alternative variants were cloned from
myoblast cells. Interestingly, two novel alternative splice variants, designated Fggy-L-482 and
Fggy-S-344, were also cloned, suggesting that at least four Fggy splice variants are expressed in
skeletal muscle. Quantitative RT-PCR (RT-qPCR) was performed using RNA isolated from
muscle cells and primers designed to distinguish the four alternative Fggy transcripts. The RTqPCR data reveals that the Fggy-L transcripts are more highly expressed during myoblast
differentiation, while the Fggy-S transcripts show relatively stable expression in proliferating
myoblasts and differentiated myotubes. Confocal fluorescent microscopy revealed that the FggyL variants appear to localize evenly throughout the cytoplasm, while the Fggy-S variants produce
a more punctuate localization pattern throughout the cytoplasm of proliferating muscle cells.
Finally, ectopic expression of Fggy-L-552 and Fggy-S-387 resulted in inhibition of muscle cell
differentiation and attenuation of the MAP kinase and AKT signaling pathways. The
characterization of novel genes induced during neurogenic atrophy helps improve our
understanding of the molecular and cellular events that lead to muscle atrophy and may eventually
lead to new therapeutic targets for the treatment of muscle wasting.
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Chapter 1: Skeletal Muscle Atrophy, MuRF1, and Muscle Cell Signaling
Skeletal Muscle Atrophy
Skeletal muscle atrophy is a decrease in the total muscle mass due to the rate of protein degradation
outpacing the rate of protein synthesis (Bodine and Baehr, 2014). This change can be caused by a
variety of physiological conditions, including aging, neuronal injury, disuse, and corticosteroid
treatment (Bodine and Baehr, 2014). Atrophy is not specific to one disease, has many levels of
severity, and is multifactorial, suggesting there may not be one simple way to prevent muscle
wasting. However, having clearer insight into how the body regulates muscle atrophy may provide
important information for the identification and development of new therapeutic targets to prevent
this process.
MuRF1 and MAFbx
To explore atrophy at the molecular level, a study using rats undergoing muscle atrophy identified
two E3 ubiquitin ligases named Muscle RING Finger 1 (MuRF1) and Muscle Atrophy F-Box
(MAFbx) as being upregulated in virtually all atrophy models, including denervation,
immobilization, unweighing, and treatment with interleukin-1 (IL-1) or dexamethasone (Bodine
et al, 2001). A number of genes were observed to have differential expression under one or two
conditions but only MuRF1 and MAFbx were found to be upregulated under all conditions (Fig.
1). This study also showed that MuRF1 and MAFbx null mice are resistant to skeletal muscle
atrophy (Bodine et al, 2001). After transection of the sciatic nerve, MuRF1 knockout mice showed
36% muscle sparing at 14 days of denervation, while MAFbx knockout mice showed 56% sparing

at 14 days post denervation (Bodine et al, 2001). These findings demonstrated that MuRF1 and
MAFbx are likely involved in a common atrophy cascade. Moreover, MuRF1 and MAFbx are
known E3 ubiquitin ligases, and believed to participate in muscle atrophy by targeting substrate
proteins for degradation via the ubiquitin proteasome pathway.

Figure 1. MuRF1 and MAFbx are upregulated during muscle atrophy. Northern blot analysis
of MuRF1 and MAFbx in muscle isolated from rats subjected to atrophy induction by
immobilization, denervation, and hind limb suspension. Increased expression of MuRF1 and
MAFbx was observed at day 1 and reached a peak at day 3 post-denervation (Bodine et al, 2001).
The Ubiquitin Proteasome System
Ubiquitin is a small, abundant protein that covalently attaches to target proteins, which frequently
leads to degradation by the 26S proteasome (Borlepawar et al, 2018). Prior to attachment to target
proteins, ubiquitin must first be activated by an E1 ubiquitin activating enzyme. The activated
ubiquitin then binds to an E2 ubiquitin conjugating enzyme, which transfers the ubiquitin to the
targeted protein with the E3 ligating enzyme serving as a platform to bring the E2 and substrate
protein into proximity (Fig. 2). Protein degradation via the Ubiquitin Proteasome System (UPS) is
very specific and although there are only two E1 enzymes (Jin et al., 2007) and about 40 E2
enzymes (Stewart et al., 2016), there are around 600 different E3 enzymes that provide substrate
specificity and allow this system to act in a precise manner (Mearini et al., 2008). UPS activity has
been characterized under multiple physiological conditions that lead to muscle loss, including
2

denervation (Medina, Wing, and Goldberg, 1995), disuse (Taillander et al, 1996), and cancer
cachexia (Temparis et al, 1994;Baracos, 1995).

Figure 2. Schematic of the ubiquitin proteasome system. The E1 ubiquitin activating enzyme,
E2 ubiquitin conjugating enzyme, and E3 ubiquitin ligase form a pathway to ubiquitinate
substrates for degradation by the 26s proteasome (Dodd, 2011).
MuRF1 as a Putative Transcriptional Regulator
MuRF1 is a member of the tripartite motif (TRIM) family of E3 ubiquitin ligases that are
characterized by a RING domain, a zinc-finger B-box domain, and a leucine-rich coiled-coil
domain (Bodine and Baehr, 2014). The RING domain of E3 ubiquitin ligases functions by bringing
substrate proteins and activated ubiquitin from the E2 into direct contact. The RING domain is
believed to perform the catalytic activity of MuRF1, while the zinc-finger B-box domain is
suggested to function in binding to target proteins (Ikeda et al, 2013).
Although there are many studies focusing on its role in the UPS, there are other studies indicating
MuRF1 may have an additional role as a transcriptional modulator (Furlow et al, 2013). One study
suggests that MuRF1 may serve as a negative transcriptional regulator of itself and of MAFbx, but
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it is unclear if this regulation is direct or indirect (Furlow et al, 2013). To investigate MuRF1
further, a MuRF1 knockout mouse was created by inserting a β-galactosidase lacZ cassette into
the MuRF1 locus, putting the β-galactosidase gene under the control of the endogenous MuRF1
promoter and creating a MuRF1 reporter gene within the mouse genome (Bodine et al, 2001).
When analyzing MuRF1 expression in denervated muscles from wild type mice, it was found that
MuRF1 levels increase by 3 days of denervation but return to baseline by 14 days of denervation
(Furlow et al, 2013). In contrast, MuRF1 gene locus activity does not return to baseline in the
MuRF1-null mice as measured by β-galactosidase expression in the KO mice, suggesting that lack
of MuRF1 leads to a failure to inhibit the MuRF1 promoter (Fig. 3A-B). Furthermore, this same
study also showed that mice lacking MuRF1 failed to down regulate MAFbx expression after 14
days of denervation (Fig. 3C-D). Finally, the microarray study revealed that MuRF1 KO leads to
differential expression of a number of other genes in response to denervation including a gene
named Fggy Carbohydrate Kinase Domain Containing (Fggy) (Furlow et al, 2013).

4

Figure 3. Transcriptional activity of the MuRF1 gene locus and MAFbx in WT and MuRF1
KO mice post-denervation. (A) Denervated WT mice show an increase in MuRF1 gene
expression at day 3 (3D) but returns to baseline at day 14 (14D) post-denervation. (B) Denervated
KO mice show an increase in β-galactosidase expression, which is under the control of the MuRF1
promoter, at day 3 and expression remained elevated at day 14 post-denervation. (C) Denervated
WT mice show an increase in MAFbx gene expression at day 3 (3D) but a return to baseline levels
by day 14 (14D) post-denervation. (D) Denervated MuRF1 KO mice showed increased expression
in MAFbx at day 3 (3D) that remained elevated at day 14 (14D) (Furlow et al, 2013).
Mitogen-activated protein kinase signaling
MAPK signaling is essential for the expression of muscle specific genes, muscle growth, and
differentiation of muscle cells (Fig. 4) (Bennett and Tonks, 1997). It has previously been shown
that MAPK signaling is critical for muscle cell differentiation, specifically complete differentiation
and fusion of myoblasts into myotubes (Bennett and Tonks, 1997). The four branches of the MAP
kinase signaling pathway include extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun
amino-terminal kinase (JNK), p38, and ERK5 (Bennett et al, 1997). Moreover, the ERK1/2 branch
has been linked to the regulation of skeletal muscle cell growth and differentiation (Bennett and
Tonks, 1997). Specifically, the inactivation of this branch has been found to promote myogenesis
5

initiation (Adi et al, 2002; Bennett and Tonks, 1997) by leading to the upregulation of
differentiation factors specific to skeletal muscle cell differentiation, including myogenin (Penna
et al, 2010). Previous work from our lab has identified a number of genes that are differentially
expressed in the MuRF1 KO model in response to denervation that are also linked to MAPK
signaling. For example, Dual-specificity phosphatase 29 (Dusp29) and Dual-specificity
phosphatase 4 (Dusp4), which are part of a large group of phosphatases that regulate the MAPK
pathway (Caunt et al., 2012), have been shown to decrease the activity of the ERK1/2 branch
(Cooper et al., 2020; Haddock et al., 2019). Further, Tetratricopeptide repeat domain containing
39C (Ttc39c) and Family with sequence similarity 83 Member D (Fam83D), which are two
putative scaffolding proteins important for modulating proper muscle cell signaling pathways,
including the ERK1/2 branch of the MAP kinase signaling cascade, have been found to be
differentially regulated in MuRF1 KO mice following denervation (Hayes et al., 2019; Cooper et
al., 2020). Additionally, protein phosphatase methylesterase (Ppme1) has been found to regulate
the MAPK signaling pathway through the ERK1/2 branch of MAP kinase signaling and inhibition
of Ppme1 led to a decrease in whole ERK1/2 expression, as well as ERK1/2 phosphorylation levels
(Labuzan et al., 2020).
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Figure 4. Schematic of the MAPK signaling pathways (Wang, Xia, 2012).

AKT signaling cascade
In addition to MAPK signaling, AKT signaling is also known to be involved in the modulation of
skeletal muscle mass (Hitachi and Tsuchida, 2014). The upstream regulator of AKT and mTOR,
insulin-like growth factor-1 (IGF-1), is responsible in part for the induction of protein synthesis
(Fig. 5) (Hitachi and Tsuchida, 2014). IGF-1 inhibits muscle atrophy and promotes muscle
hypertrophy by activation of the AKT signaling pathway, which is known to promote protein
synthesis in three ways; 1) by inhibition of GSK-3β, 2) by inhibition of the FoxO family of
transcription factors, and 3) by activation of the mTOR pathway (Hitachi and Tsuchida, 2014).
Glycogen synthase kinase 3 β (GSK-3β) is constitutively active and functions by inhibiting protein
synthesis (MacAulay and Woodgett, 2008). Activated AKT phosphorylates GSK-3β to inactivate
it, which allows its target proteins to become dephosphorylated (MacAulay and Woodgett, 2008).
Forkhead box O (FoxO) is a family of transcription factors that activate the transcription of MuRF1
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and MAFbx and promote muscle atrophy (Sandri et al., 2004). AKT phosphorylation of FoxO
transcription factors inhibits their translocation into the nucleus and ability to activate atrophy
promoting genes (Sandri et al., 2004). The activation of mTOR by AKT allows it to phosphorylate
4E-BP1 which prevents it from binding and inactivating the initiation factor eIF4E, which leads to
the release of eIF4E and a concomitant increase in protein translation levels within the muscle cell
(Alessi et al., 1996; Tsai et al., 2015). Overall, the activation of the AKT signaling cascade results
in a decrease in protein degradation via FoxO inactivation and an attenuation of MuRF1 and
MAFbx activation. Moreover, AKT activation also leads to an increase in protein synthesis via
GSK-3β inhibition and mTOR activation, which promotes muscle hypertrophy.

Figure 5. Schematic of the AKT signaling pathway in skeletal muscle (Hitachi and Tsuchida,
2014).
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Chapter 2: Identification and characterization of Fggy carbohydrate kinase domain
containing in skeletal muscle
Introduction
The FGGY Carbohydrate Kinase Family
The Fggy gene belongs to an evolutionarily related family of carbohydrate kinases that have been
found to phosphorylate an array of various sugar substrates (Zhang et al., 2011). The Fggy
carbohydrate kinase family includes, L-fucolokinase, gluconokinase, glycerol kinase, D-ribulose
kinase, and L-xylulose kinase (Omelchenko et al., 2010). Of these, the glycerol kinases are the
most widely conserved between the three domains of life (Fig. 6).

Figure 6. Phylogenetic tree of the Carbohydrate kinases of the FGGY family (Omelchenko et
al., 2010).
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The FGGY kinase family also consists of a subgroup, similar to the xylulose kinase, that
phosphorylates autoinducer-2 (AI-2). AI-2 is a bacterial signaling molecule that plays a role in
regulating bacterial behaviors such as cell to cell communication, biofilm formation, and gene
expression (Xavier et al., 2007; Vendeville et al., 2005). Additionally, the rate of AI-2 synthesis
and uptake has been shown to be elevated in the presence of glucose (Wang et al., 2005). Although
characterization of the functional role of this diverse family of kinases remains ongoing, it is
known that they possess two conserved domains referred to as the N-terminal (FGGY-N) and Cterminal (FGGY-C) (Hurley et al., 1996; Hurley et al., 1993). The two domains both adopt a
ribonuclease H-like fold and the cleft formed between the two domains acts as the binding site for
substrates, as well as ATP (Hurley et al., 1993).
Fggy carbohydrate kinase domain-containing
The Fggy carbohydrate kinase domain-containing gene (Fggy) encodes a protein with at least 90%
conservation between humans, mice, and rats (Madiera et al., 2019). In humans, it is found on the
short arm of the first chromosome and in mice it is found on the fourth chromosome.
A previous study in HEK293 cells found that Fggy may function in the pentose phosphate pathway
(also known as the phosphogluconate pathway or hexose monophosphate shunt) and is a metabolic
pathway that runs parallel to glycolysis, but appears to play a primary role in the generation of
precursors for the synthesis of nucleotides (Fig. 7) (Singh et al., 2017; Ge et al., 2020). Fggy has
previously been suggested to be associated with sporadic amyotrophic lateral sclerosis (S-ALS)
(Dunckley et al., 2007), but further studies have failed to corroborate these results which might be
due to the complexity of this multifactorial disease (Doud et al., 2012 and Cai et al., 2014).
Although previous studies have not generated a consensus regarding a role for Fggy in S-ALS
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development of progression, it is an intriguing possibility since we identified Fggy as a novel
neurogenic atrophy-induced gene in skeletal muscle.

Figure 7. Schematic of the pentose phosphate pathway (PPP). Enzymes in the oxidative and
non-oxidative PPP are shaded in green (Ge et al., 2020).
In addition to a putative role in skeletal muscle, Fggy has also been identified as a tumor
suppressor gene and as a potential biomarker for the severity of lung squamous cell carcinoma
(LUSC) due to an observed negative relationship between the expression of a Fggy mutant isoform
and LUSC prognosis (Zhang et al., 2019). Specifically, poor LUSC clinical outcomes have been
linked to a specific mutant variant of the Fggy gene designated LINE-1-FGGY (L1-FGGY). L1FGGY is generated when a transposon, called the long-interspersed element 1 (LINE-1), is inserted
into the beginning of the thirteenth exon of Fggy via retro-transposition which inactivates the Fggy
gene (Zhang et al 2019). Inactivation of the Fggy gene resulted in increased cell proliferation and
dysregulation of cell energy metabolism further suggesting a role of Fggy in energy metabolism
and identifying a new role for Fggy in regulating cell proliferation (Zhang et al 2019). Finally, in
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adipose tissue, a low dose of bisphenol A (BPA) exposure in fetal mice decreased the instance of
hypermethylation of the Fggy promoter which lead to an increase in Fggy transcription (Taylor et
al., 2018). As a result, an increase in the amount of adipose tissue and diet induced obesity in adult
mice was observed (Taylor et al., 2018). Previous studies linking Fggy to cell metabolism, adipose
tissue development, and regulation of cell proliferation provide intriguing insights into the
potential functional role that Fggy may play in the molecular mechanisms of skeletal muscle
atrophy. Here, we present the first investigation of the role that Fggy plays in skeletal muscle.

Materials and Methods
Animals
There were no animal experiments related to the current study conducted at the University of North
Florida; however, the sex, age range, strain, and treatment conditions of the animals used for the
Illumina array studies, as well as the IUCAC approvals, have been previously described (Furlow
et al., 2013)
Cell Culture
C2C12 mouse myoblasts were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM)
(Thermo Fischer Scientific, Waltham, MA) supplemented with 1X Penicillin/Streptomycin and
Gentamicin (Thermo Fischer Scientific, Waltham, MA), non-essential amino acids (GE
Healthcare HyClone Laboratories, Logan, UT), and 10% Fetal Bovine Serum (FBS) (GE
Healthcare HyClone Laboratories, Logan, UT). Cells were grown in a humidified chamber at 37°
C and 5% CO2. DMEM with 2% FBS, Penicillin/Streptomycin and Gentamicin, and non-essential
amino acids was used to induce C2C12 myoblast differentiation when cells reached 100%
confluency.
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RNA isolation and complementary DNA synthesis
Total RNA was isolated from C2C12 cells using the RNeasy Mini Kit (Qiagen, Valencia, CA) and
following the manufacturer’s instructions. Isolated RNA was used to synthesize complementary
DNA (cDNA) using a PolyT primer and Moloney Murine Leukemia Virus (M-MLV) Reverse
Transcriptase (Thermo Fisher Scientific, Waltham, MA) and following the manufacturer’s
instructions.
Cloning of the Fggy cDNA
Gene specific primers (Table 1) were designed using the gene sequences for murine Fggy-L
(GenBank accession number: NM_001113412.1) and Fggy-S (GenBank accession number:
NM_029347.2) and mixed with template DNA generated by reverse transcription as described
above, and Taq polymerase. PCR reactions were performed by following the manufacturer’s
protocol (Life Technologies, Grand Island, NY).
Fggy open reading frames (ORFs) were cloned into the pGEM-T Easy vector using the
manufacturer’s provided protocol (Promega, Madison, WI) and sequenced to confirm the absence
of mutations using the Big Dye Sanger terminator sequencing method (Eurofins MWG Operon,
Huntsville, AL). Fggy ORFs were sub-cloned into the HindIII and BamHI restriction sites of the
pcDNA3.1 1(+) (ThermoFisher Scientific, Waltham, MA) and pEGFP-C3 (Clontech, Mountain
View, CA) expression plasmids and sequenced to confirm correct orientation.
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Table 1. Primer Sequences (5’ to 3’)
Primer Name

Sequence

Fggy-cDNA3-L-552-F

GCAAGCTTACCATGATGTCTGGCAGAGACCAGG

Fggy-cDNA3- L-552-R

GCGGATCCGGACAGGTATGTTCAGCTTCCATTCATG

Fggy-cDNA3-S-387-F

GCAAGCTTACCATGATGTCTGGCAGAGACCAGG

Fggy-cDNA3- S-387-R

GCGGATCCGCATTCTTAAAATGCTTTAGAAGAAG

Fggy-L-482-qPCR-F

AGATCCAGTGTTTGTACCAGG

Fggy-L-482-qPCR-R

CCAGTGACCAATTTTCCAGTC

Fggy- L-552-qPCR-F

ATGGCAACCGGTCTCCCTTAG

Fggy- L-552-qPCR-R

TTGAACAGTGGCCAGGTAGAG

Fggy-S-344-qPCR-F

GCAAAATAGGAGTGATTGGGG

Fggy-S-344-qPCR-R

CACTGGATCTTTGCTGATCCC

Fggy- S-387-qPCR-F

ATCGTCCCTGGGTTCTGGTTG

Fggy- S-387-qPCR-R

CTGTAGGTTTCTGGCTGTGGC

Reporter Assays
Mouse myoblasts were plated in 12-well dishes at approximately 75,000 cells/well and allowed to
proliferate overnight prior to transfection. Transfections were performed at 70-80% confluence
using Turbofect Transfection Reagent (Thermo Scientific, Rockford, IL) and following the
manufacturer's protocol. Cells were overlaid with 1 μg per well of total DNA, including
250 ng/well of reporter plasmid, 125 ng/well of β -galactosidase (β-gal) as an internal control, and
14

empty pBluescript plasmid to a final concentration of 1 µg/well. The DNA had been allowed to
complex with the transfection reagent for 20 minutes prior to cell overlay. After 24 hours, culture
media was changed from 10% to 2% serum to induce differentiation. Media was harvested at 48
h, 96 h, and 144 h post-media change to analyze secreted embryonic alkaline phosphatase (SEAP)
levels. The Phospha-Light SEAP Reporter Gene Assay Kit (Life Technologies, Grand Island, NY)
was used per the manufacturer’s instructions protocol to detect SEAP levels using a Biotec
Synergy 2 microplate reader set for an endpoint read with a 2 s integration time to assess levels of
luminescence. To adjust for variations in transfection efficiency between wells, β -gal activity was
analyzed. Cells were lysed with Passive Lysis Buffer (Promega, Madison, WI) and homogenates
cleared by

centrifugation.

Cell

lysates

were incubated with

ortho-nitrophenyl-β-D-

galactopyranoside (ONPG) dissolved in Z Buffer (60 mM Na2HPO4·7H2O, 40 mM
NaH2PO4·H2O, 10 mM KCl, 1 mM MgSO4, 50 mM β-mercaptoethanol, pH 7.0) overnight at 37
°C. SEAP activity was divided by the β -gal activity to achieve corrected SEAP values.
Reverse transcription quantitative PCR
Reverse transcription quantitative PCR (RT-qPCR) was carried out using total RNA isolated from
C2C12 cells and the iScript cDNA Synthesis Kit according to the manufacturer’s protocol (Bio‐
Rad, Hercules, CA). The reverse transcription of isolated RNA yielded complementary DNA
(cDNA) that was then used for analysis of Fggy gene expression in C 2C12 cells. Gene specific
primers (Table 1) cDNA, and iTaq Universal SYBR Green Reaction Supermix were mixed
according to the manufacturer’s instructions (Bio-Rad, Hercules, CA) and analyzed on the CFX
Connect Real-Time PCR Detection System (Bio-Rad, Hercules, CA). The experiment was
repeated as least two times and each condition was performed in biological triplicate, each
individual biological replicate was used for cDNA amplification in duplicate, and each cDNA
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amplification replicate was done in technical triplicates (three biological replicates × two cDNA
synthesis replicates × three technical replicates = 18 individual reads per biological sample). The
Fggy expression data was calculated after normalization to GAPDH expression using the
2−ΔΔCt method.
Protein purification and Western blot analysis
Protein purification was achieved as previously described (Haddock et al., 2019, Hayes et al.,
2019, Lynch et al., 2019). Briefly, mouse myoblasts were cultured in 10 cm plates, harvested at
various timepoints, and lysed for protein isolation. Fggy was exogenously expressed by
transfection of cells with pcDNA3.1-Fggy expression plasmids after 24 hours of cell growth in
10% FBS media using Turbofect transfection reagent according to the manufacturer’s instructions.
Cells were then harvested at various timepoints of proliferation and differentiation and stored at
−80 °C until cell lysis. Cells were lysed on ice in Universal Lysis Buffer (ULB) (+) (50 mM Tris,
pH 7.5, 150 mM NaCl, 50 mM NaF, 0.5% NP-40, with addition of 1 mM PMSF, 1 mM DTT,
10 mM β-glycerophosphate, 2 mM sodium molbydate and a protease inhibitor cocktail), cleared
by centrifugation, and total protein concentration was determined using the Quick Start Bradford
1X Dye Reagent and following the manufacturer’s instructions (Bio-Rad, Hercules, CA).
Western blot procedures were conducted using 25-100 μg of protein run on a sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS PAGE) denaturing gel and transferred to
polyvinylidene fluoride (PVDF) membrane (EMD Millipore, Billerica, MA). To verify the quality
of the transfer and equal protein loading, the membranes were stained using Ponceau S prior to
blocking the membrane in 5% dry milk dissolved in Tris-buffered saline and 0.05% Tween-20
(TTBS). The membranes were probed with anti-myosin heavy chain (MYH1/2/4/6), antimyogenin, anti-p-ERK, anti-ERK, anti-AKT-phospho-S473, anti-AKT, anti-GAPDH, and anti-α
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tubulin primary antibodies and subsequently probed with a corresponding HRP-conjugated
secondary (Table 2). Westerns were developed by incubating the membrane with ECL Western
Blotting Substrate (Thermo Fisher Scientific, Waltham, MA) and imaged using the Amersham
Imager 600 RGB system (GE Healthcare Life Sciences, Marlborough, MA). For the use of
multiple antibodies on a single blot, membranes were striped with a 10% SDS, 0.5 M Tris-HCl pH
6.8, β-mercaptoethanol solution, blocked again, and then probed and imaged as described
previously. The intensity of the bands on the Western blots was quantified using the open access
ImageJ software.
Table 2. List of antibodies used in this study
Antibody

Source

Catalog #

Dilution

anti-α-tubulin

Santa Cruz Biotechnology, Dallas, TX

sc-32293

WB: 1:1000

anti-Myosin Heavy Chain Santa Cruz Biotechnology, Dallas, TX

sc-32732

WB: 1:1000

(MYH1/2/4/6)
anti-myogenin

Santa Cruz Biotechnology, Dallas, TX

sc-12732

WB: 1:1000

anti-GAPDH

ProteinTech, Rosemont, IL

600041-lg

WB: 1:5000

anti-phospho-ERK

Santa Cruz Biotechnology, Dallas, TX

sc-7383

WB: 1:1000

anti-ERK

Santa Cruz Biotechnology, Dallas, TX

sc-94

WB: 1:1000

anti-Akt1-phospho-S473

ProteinTech, Rosemont, IL

66444-I-lg

WB: 1:2000

anti-Akt

ProteinTech, Rosemont, IL

602032-lg

WB: 1:5000

sc-2357

WB: 1:5000

PI31450

WB: 1:5000

Mouse anti-rabbit IgG- Santa Cruz Biotechnology, Dallas, TX
HRP
Rabbit anti-mouse IgG- Thermo Scientific, Rockford, IL
HRP (H + L)
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Confocal fluorescent microscopy
Mouse myoblast cells were plated on 3.5 cm glass bottom plates at a seeding density of
approximately 100,000 cells/plate and transfected with 2.5 μg of pEGFP-Fggy expression
plasmids at 70-80% confluency. Cells were fixed at 48h post-plating with 4% paraformaldehyde
dissolved in 0.1 M NaCacodylate and DRAQ5 nuclear stain was used to visualize cell nuclei
(ThermoFisher Scientific, Waltham, MA). Imaging was conducted on an Olympus Fluoview FV1000 confocal fluorescent microscope with a Super Apochromat UPLSAPO 20X objective or a
Super Apochromat UPLSAPO 60×W objective. The GFP and DRAQ5 images were then merged
using the open access ImageJ software and utilizing the Open Microscopy Environment BioFormats software plugin tool.
Statistics
The data are presented as the mean ± standard deviation (±SD). Statistical analysis was conducted
using a two-tailed t-test and a P value ≤ 0.05 was considered significant.

Results
Fggy is induced during skeletal muscle atrophy
To identify genes that are differentially expressed in response to neurogenic atrophy, RNA was
harvested from the triceps surae (TS) muscle of mice following 3 and 14 days of denervation as
previously described (Furlow et al., 2013). A significant number of genes that have not previously
been studied in skeletal muscle were shown to be differentially expressed in response to
neurogenic skeletal muscle atrophy, including Fggy carbohydrate kinase domain containing
(Fggy). At 3-days post denervation, Fggy showed a small but significant increase in expression
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compared to control muscles while at 14-days post denervation, the increase in Fggy expression
was greater compared to the control muscles (Fig. 8).

✱✱

✱✱✱✱

Figure 8. Fggy is induced in response to denervation-induced skeletal muscle atrophy. Whole
genome expression analysis was conducted on triceps surae muscle from wild-type (WT) mice
after 3 days (3D) and 14 days (14D) of denervation (DEN). Each condition represents the average
expression from three animals and error bars represent ± SD. White bars represent the controls and
gray bars represent DEN. Significant difference between denervated mice and control mice in the
same group, P < 0.05. Fggy-L was recognized by a probe on exon 16 and expression showed a
significant increase in atrophic conditions at 3D and 14D post denervation.
Fggy-L and Fggy-S are alternatively spliced in muscle cells
Fggy has been shown to be most abundantly expressed in liver but is also found to be expressed
in skeletal muscle (Fagerberg et al., 2014), which is not unexpected considering this gene may
play a role in carbohydrate metabolism. This study is the first to identify four alternative Fggy
isoforms simultaneously expressed in muscle cells, two of which are completely novel (Fig. 9AB). We have designated these four isoforms as Fggy-Long form, which consists of 552 amino acids
(Fggy-L-552), an alternative Fggy-Long form consisting of 482 amino acids (Fggy-L-482), FggyShort form consisting of 387 amino acids (Fggy-S-387), and an alternative Fggy-Short form
consisting of 344 amino acids (Fggy-S-344) (Fig. 9A-B). The two novel transcripts are shorter
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than their previously identified counterparts with Fggy-L-482 lacking exons 10 and 11 and FggyS-344 lacking exon 7 (Fig. 9A-B). The Fggy-S-387 isoform differs from the Fggy-L-552 isoform
at amino acids 360 to 387 and is lacking amino acids 388-552. Bioinformatic analysis of the Fggy
gene in both humans and rodents revealed a locus that generates numerous splice variants and has
8 putative protein encoding isoforms in mice that result from alternative splicing and/or alternative
transcription initiation sites. Of the 8 putative protein encoding transcripts of the murine Fggy
gene, 2 have been added to the CCDS database. The first isoform we have designated as Fggy-L552 (CCDS51233), which consists of 16 exons and 15 introns and has a predicted molecular weight
of approximately 60 kDa. The second isoform we have designated as Fggy-S-387 (CCDS18365),
which consists of 11 exons and 10 introns and produces a protein with a predicted molecular weight
of approximately 42.5 kDa. Interestingly, both isoforms retain the conserved FGGY-N and FGGYC domains characteristic of the FGGY carbohydrate kinase family.
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Figure 9. Schematics of alternative transcripts of Fggy-L and Fggy-S. (A) Fggy-L-552 has 16
exons and 15 introns and an alternative transcript without exons 10 and 11 (red circle) named
Fggy-L-482 for the number of amino acids in the protein sequence. The schematic of the Fggy
genes structure was downloaded from the Ensembl database (www.ensembl.org). (B) Fggy-S-387
has 11 exons and 10 introns and an alternative transcript without exon 7 (red circle) named FggyS-344. The schematic of the Fggy genes structure was downloaded from the Ensembl database
(www.ensembl.org).
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Fggy-L is upregulated during muscle cell differentiation
To analyze the expression profile of Fggy in proliferating myoblasts and differentiated myotubes,
qPCR primers were designed distinguish between the four alternative splice variants. C 2C12 cells
were harvested at proliferation day 2 (PD2), differentiation day 2 (DD2), and differentiation day
7 (DD7). RNA was isolated and used for analysis of Fggy expression by reverse transcription
quantitative polymerase chain reaction (RT-qPCR). The results show that the expression of the
Fggy-L isoforms peak during early differentiation (Fig. 10A-B), while the expression of the FggyS isoforms remains relatively constant between proliferation and differentiation (Fig. 10C-D).
A.

B.
✱✱
✱✱✱

✱✱

C.

D.

Figure 10. Expression pattern analysis of the Fggy isoforms in cultured muscle cells. RTqPCR analysis of the (A) Fggy-L-552, (B) Fggy-L-487, (C) Fggy-S-384, and (D) Fggy-S-344
transcripts in proliferating (PD2) myoblasts and early (DD2) and late differentiated (DD7)
myotubes. Significant difference between proliferating (PD2) and differentiated cells (**: P < 0.01,
***:P <0.001).
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Fggy localizes to the cytoplasm of myoblasts
To elucidate the sub-cellular location of Fggy in muscle cells, pEGFP-Fggy-L and pEGFP-FggyS expression plasmids were created and transfected into C 2C12 cells. The Fggy-L isoforms both
show a diffuse and uniform cytoplasmic localization pattern (Fig. 11), while the Fggy-S isoforms
show a more punctate cytoplasmic localization pattern (Fig. 12) These distinct localization patterns
may be due to the Fggy-L isoforms possessing a 165 amino acid c-terminal tail region that is
missing in the Fggy-S isoforms (Fig. 13).

Figure 11. Fggy-L isoforms localize to the cytoplasm in C 2C12 cells. C2C12 cells that were
transfected with pEGFP-Fggy-L expression plasmids and imaged at 60X. Fggy-L-552 (Panels 13) and Fggy-L-482 (Panels 4-6) were found to localize to the cytoplasm of myoblasts. Nuclei were
visualized using Draq5. Scale bar = 25 µm
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Figure 12. Fggy-S isoforms localize to the cytoplasm in a punctate pattern in C 2C12 cells.
C2C12 cells that were transfected with pEGFP-Fggy-S expression plasmids and imaged at 60X.
Fggy-S-387 (Panels 1-3) and Fggy-S-344 (Panels 4-6) were found to localize in a punctate pattern
to the cytoplasm of myoblasts. Nuclei were visualized using Draq5. Scale bar = 25 µm
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Figure 13. Alignment of the Fggy protein sequences. The amino acid sequences of the four
murine Fggy isoforms aligned using the ClustalW2 algorithm and shaded using Boxshade.
Ectopic Fggy expression attenuates muscle cell differentiation
To determine the effect of Fggy overexpression on muscle cell differentiation, the pcDNA3-FggyL-552 and pcDNA3-Fggy-S-387 expression plasmids were used to transfect C 2C12 cells. The cells
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were then harvested over a differentiation time course, lysed, and protein homogenates were used
for Western blot analysis of known markers of muscle cell differentiation. Myosin heavy chain
(MyHC) and myogenin both showed significantly blunted expression in response to ectopic
expression of Fggy-L-552 and Fggy-S-387 at all differentiation timepoints (Fig. 14A and 15A).
To confirm Fggy-mediated inhibition of muscle cell differentiation, biological quadruplicates of
Fggy-L-552 or Fggy-S-387 overexpressing cells were harvested at differentiation day 2 and
analyzed by Western blot (Fig. 14B and 15B). Quantification of the Western blots for MyHC and
myogenin protein levels confirmed a statistically significant reduction in both (Fig. 14C and 15C).
GAPDH expression was analyzed to verify equal protein loading.
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Figure 14. Ectopic expression of Fggy-L attenuates muscle cell differentiation. C2C12 cells
were transfected with the pcDNA-Fggy-L-552 expression plasmid. Cells were maintained in 10%
serum media for the proliferation timepoints and switched to 2% serum media to induce
differentiation. Cells were harvested at proliferation day 2 (PD2) and differentiation days 1, 3, and
5 (DD1, DD3, DD5). (A) Western blot analysis of the differentiation markers Myosin Heavy Chain
(MyHC) and myogenin showed significantly lower levels of expression at DD3 and DD5 in
response to Fggy-L-552 overexpression. (B) C2C12 cells were transfected with the pcDNA-FggyL-552 expression plasmid in biological quadruplicates, maintained in proliferation media, and then
switched to differentiation media (2% serum) for 2 days. Western blot analysis of MyHC and
myogenin using protein homogenates from C2C12 cells differentiated for 2 days. (C) Quantification
of the Western blot band intensities from part B. Relative intensity of each band was corrected to
the GAPDH band intensity for each corresponding biological replicate. Significant differences
between control cells compared to cells ectopically expressing Fggy-L-552, (*: P < 0.05, **: P <
0.01).
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Figure 15. Ectopic Fggy-S expression attenuates muscle cell differentiation. C2C12 cells were
transfected with the pcDNA-Fggy-S-387 expression plasmid. Cells were maintained in 10% serum
media for the proliferation timepoints and switched to 2% serum media to induce differentiation.
Cells were harvested at proliferation day 2 (PD2) and differentiation days 1, 3, and 5 (DD1, DD3,
DD5). (A) Western blot analysis of the differentiation markers Myosin Heavy Chain (MyHC) and
myogenin showed significantly lower levels of expression at DD3 and DD5 in response to FggyS-387 overexpression. (B) C2C12 cells were transfected with the pcDNA-Fggy-S-387 expression
plasmid in biological quadruplicates, maintained in proliferation media, and then switched to
differentiation media (2% serum) for 2 days. Western blot analysis of MyHC and myogenin using
protein homogenates from C2C12 cells differentiated for 2 days. (C) Quantification of the Western
blot band intensities from part B. Relative intensity of each band was corrected to the GAPDH
band intensity for each corresponding biological replicate. Significant differences between control
cells compared to cells ectopically expressing Fggy-L-552, (**: P < 0.01, ***: P < 0.001).
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Fggy overexpression inhibits MAPK signaling
To evaluate the impact of Fggy overexpression on pathways critical for muscle cell differentiation,
Fggy-L-552, Fggy-L-482, Fggy-S-387, and Fggy-S-344 were overexpressed individually in C 2C12
cells along with an activator protein-1 (AP-1) reporter gene plasmid. As one of the terminal targets
of the MAPK signaling pathway, AP-1 activity can be used to measure the activity of the MAPK
signaling pathway. Culture media was harvested, and SEAP activity was measured, revealing that
all four Fggy isoforms inhibited MAPK signaling (Fig. 16). Phosphorylation levels of ERK1/2
were then analyzed via western blot. Phosphorylated ERK1/2 (p-ERK1/2) levels were found to be
lower in cells ectopically expressing Fggy-L-552 (Fig. 17A) or Fggy-S-387 (Fig. 18A). To confirm
inhibition of ERK1/2 phosphorylation levels, biological quadruplicates of Fggy-L-552 or Fggy-S387 overexpressing cells were harvested at differentiation day 2 and analyzed by Western blot
(Fig. 17B and 18B). Quantification of the Western blots for ERK1/2 protein and p-ERK1/2 levels
confirmed a statistically significant reduction in phosphorylated ERK1/2 (Fig. 17C and 18C).

Figure 16. Ectopic expression of Fggy inhibits MAPK signaling. C2C12 cells were transfected
with pcDNA3-Fggy-L-552, pcDNA3-Fggy-L-482, pcDNA3-Fggy-S-387, or pcDNA3-Fggy-S344 expression plasmids along with a MAP kinase signaling pathway reporter gene. SEAP activity
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was measured by harvesting culture media 72 hours post-media change. Cells ectopically
expressing Fggy showed significantly less SEAP activity. (*:P < 0.05, **:P < 0.01)

Figure 17. Ectopic expression of Fggy-L inhibits the ERK1/2 branch of the MAPK signaling
cascade. C2C12 cells were transfected with the pcDNA-Fggy-L-552 expression plasmid. Cells were
maintained in 10% serum media for the proliferation timepoints and switched to 2% serum media
to induce differentiation. Cells were harvested at proliferation day 2 (PD2) and differentiation days
1, 3, and 5 (DD1, DD3, DD5). (A) Western blot analysis of ERK1/2 and phospho-ERK1/2 showed
significantly lower levels at all time points in response to Fggy-L-552 overexpression. (B) C 2C12
cells were transfected with the pcDNA-Fggy-L-552 expression plasmid in biological
quadruplicates, maintained in proliferation media, and then switched to differentiation media (2%
serum) for 2 days. Western blot analysis of ERK1/2 and phosphor-ERK1/2 using protein
homogenates from C2C12 cells differentiated for 2 days. (C) Quantification of the Western blot
band intensities from part B. Relative intensity of each band was corrected to the GAPDH band
intensity for each corresponding biological replicate. Significant differences between control cells
compared to cells ectopically expressing Fggy-L-552, (*: P < 0.05, ns = no significance).
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Figure 18. Ectopic expression of Fggy-S inhibits the ERK1/2 branch of the MAPK signaling
cascade. C2C12 cells were transfected with the pcDNA-Fggy-S-387 expression plasmid. Cells were
maintained in 10% serum media for the proliferation timepoints and switched to 2% serum media
to induce differentiation. Cells were harvested at proliferation day 2 (PD2) and differentiation days
1, 3, and 5 (DD1, DD3, DD5). (A) Western blot analysis of ERK1/2 and phospho-ERK1/2 showed
significantly lower levels at all time points except DD3 in response to Fggy-S-387 overexpression.
(B) C2C12 cells were transfected with the pcDNA-Fggy-S-387 expression plasmid in biological
quadruplicates, maintained in proliferation media, and then switched to differentiation media (2%
serum) for 2 days. Western blot analysis of ERK1/2 and phosphor-ERK1/2 using protein
homogenates from C2C12 cells differentiated for 2 days. (C) Quantification of the Western blot
band intensities from part B. Relative intensity of each band was corrected to the GAPDH band
intensity for each corresponding biological replicate. Significant differences between control cells
compared to cells ectopically expressing Fggy-L-552, (*: P < 0.05, ns = no significance).

Overexpression of Fggy destabilizes AKT
In addition to the MAPK signaling pathway, AKT has been found to modulate muscle cellular
differentiation (Coleman et al., 1995). In response to Fggy-L-552 and Fggy-S-387 overexpression,
AKT protein and phosphorylation levels were found to be significantly lower over a differentiation
time course (Fig. 19A and 20A). To confirm AKT destabilization and inhibition of AKT
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phosphorylation levels, biological quadruplicates of Fggy-L-552 or Fggy-S-387 overexpressing
cells were harvested at differentiation day 2 and analyzed by Western blot (Fig. 19B and 20B).
Quantification of the Western blots for AKT protein and p-AKT levels confirmed a statistically
significant reduction in both AKT protein levels and phosphorylated AKT (Fig. 19C and 20C).

Figure 19. Ectopic expression of Fggy-L destabilizes AKT in muscle cells. C2C12 cells were
transfected with the pcDNA-Fggy-L-552 expression plasmid and harvested at proliferation day 2
(PD2) and differentiation days 1, 3, and 5 (DD1, DD3, DD5). (A) Western blot analysis showed
reduced levels of phosphorylated AKT with Fggy over expression at all timepoints. (B) C 2C12 cells
were transfected with the pcDNA-Fggy-L-552 expression plasmid in biological quadruplicates,
maintained in proliferation media, and then switched to differentiation media (2% serum) for 2
days. Western blot analysis of p-AKT and AKT using protein homogenates from C 2C12 cells
differentiated for 2 days. (C) Quantification of the Western blot band intensities from part B.
Relative intensity of each band was corrected to the GAPDH band intensity for each corresponding
biological replicate. Significant differences between control cells compared to cells ectopically
expressing Fggy-L-552, (*: P < 0.05,**: P < 0.01).
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Figure 20. Ectopic expression of Fggy-S destabilizes AKT in muscle cells. C2C12 cells were
transfected with the pcDNA3-Fggy-S-387 expression plasmid and harvested at proliferation day 2
(PD2) and differentiation days 1, 3, and 5 (DD1, DD3, DD5). (A) Western blot analysis showed
lower levels of phosphorylated AKT with Fggy overexpression at all timepoints except DD5. (B)
C2C12 cells were transfected with the pcDNA-Fggy-S-387 expression plasmid in biological
quadruplicates, maintained in proliferation media, and then switched to differentiation media (2%
serum) for 2 days. Western blot analysis of p-AKT and AKT using protein homogenates from
C2C12 cells differentiated for 2 days. (C) Quantification of the Western blot band intensities from
part B. Relative intensity of each band was corrected to the GAPDH band intensity for each
corresponding biological replicate. Significant differences between control cells compared to cells
ectopically expressing Fggy-S-387, (**: P < 0.01, ****: P < 0.0001).
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Discussion
Fggy may regulate muscle cell differentiation through modulation of the MAPK pathway
The levels of Fggy-L transcript were highest during differentiation, leading us to investigate the
effect of ectopic expression of Fggy on the induction of MyHC and myogenin during muscle cell
differentiation. In this study, we found that Fggy overexpression resulted in the inhibition of both
MyHC and myogenin expression, suggesting attenuation of muscle cell differentiation. Although
this data provides evidence that Fggy may play a role in proper muscle cell differentiation, it also
suggests a more complex interaction with myogenin, since myogenin expression also increases in
response to skeletal muscle atrophy induced by denervation (Moresi et al., 2010, Furlow et al.,
2013). The mechanism by which Fggy inhibits muscle differentiation remains to be fully
elucidated; however, we did find that overexpression of any of the Fggy isoforms was sufficient
to inhibit the MAPK signaling pathway. It has previously been shown that MAP kinase signaling
is necessary for the proper differentiation of myotubes (Cooper et al., 1982) and may occur through
any of four distinct branches, including the extracellular signal-related kinase 1/2 (ERK1/2), p38,
c-Jun N-terminal kinase (JNK), or ERK5 (Cargnello and Roux, 2011). Therefore, we wanted to
determine which of these branches might be regulated by Fggy and, based on previous studies
from our lab, we hypothesized that Fggy may target the ERK1/2 branch in muscle cells (Haddock
et all, 2019, Hayes et al., 2019, Cooper et al., 2020, Labuzan et al., 2020). Western blot analysis
showed that Fggy overexpression in C 2C12 cells decreased phosphorylation of ERK1/2 and
inhibited an AP-1 reporter gene. The ERK1/2 branch varies in activity during the progression from
myoblast to myotube and finally to myotube fusion. ERK1/2 phosphorylation is highest during
proliferation and late differentiation and plays a role in both the initiation of myogenesis and
myotube fusion (Bennett and Tonks, 1997). The results from this current study, showing that
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overexpression of Fggy may attenuate the MAPK pathway, suggest a possible mechanism by
which Fggy functions in regulating muscle cell differentiation.
Fggy may contribute to protein degradation through AKT inhibition
The AKT pathway is also involved in muscle cell differentiation and Fggy overexpression was
shown to decrease protein and phosphorylation levels of AKT. Interestingly, a previous study
found that elevated levels of Fggy expression in adipose tissue were positively correlated with
obesity in male mice exposed to low doses of BPA (Taylor et al., 2018). Due to their coordinated
role in energy metabolism, the relationship between adipose tissue and skeletal muscle is well
established if not fully understood. Indeed, a recent study showed that transplantation of adipose
tissue from mice that regularly trained on a running wheel into sedentary mice resulted in improved
insulin-stimulated glucose uptake in the skeletal muscle of the sedentary mice (Stanford et al.,
2015). Insulin induced AKT signaling modulates adipose tissue metabolism by increasing cellular
glucose uptake, protein synthesis, and synthesis of new fatty acids (Zhang and Liu, 2014). The
involvement of AKT in lipid and glucose metabolism provides a possible method by which Fggy
may participate in the regulation of fat deposition. Taylor et al. found evidence of a positive
relationship between Fggy expression and levels of adipose tissue, while our data showed that
increased Fggy expression decreases AKT expression. While these findings, might seem
contradictory as the activation of AKT leads to the synthesis of new fatty acids, Fggy may have a
muscle specific function that differs from its role in adipose tissue. In 2019 it was found that obese
adipose tissue accelerated denervation-induced muscle atrophy through FoxO activation and an
increased expression of FoxO target genes associated with atrophy (Zhu et al, 2019). This data
also supports the hypothesis that induction of Fggy during muscle atrophy may lead to the negative
regulation of AKT signaling and block AKT-mediated inhibition of the transcriptional activation
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of atrophy-promoting genes, including MuRF1 and MAFbx. The activation of these genes may
then lead to protein degradation, muscle wasting, and weakness, further suggesting that the
increase in Fggy expression in response to denervation may contribute to muscle wasting

Future Directions
Characterize the regulation of Fggy splice variant expression in muscle cells
The identification and characterization of Fggy in skeletal muscle expands our understanding of
the molecular mechanisms of skeletal muscle atrophy. In this study, we found that the Fggy gene
produces two novel transcripts in skeletal muscle in addition to two transcripts that have previously
been validated. The expression of these novel transcripts in skeletal muscle suggests that Fggy
may have a muscle specific function. The levels of the two Fggy-L transcripts were found to be
increased during differentiation, while the two Fggy-S transcripts did not change significantly
between proliferation and differentiation. Proper muscle cell differentiation is regulated by the
expression of myogenic regulatory factors (MRF’s), with MyoD and Myogenin found to be most
active during early myoblast differentiation (Bentzinger et al., 2012). MRF’s function by binding
to a DNA sequence, called an E-box, with their conserved helix-loop-helix domain. These binding
sequences are often found in the promoter regions of muscle-specific genes (Berkes and Tapscott,
2005). Both MyoD and myogenin have also been shown to increase in expression during
neurogenic skeletal muscle atrophy (Merlie et al., 1994). The upregulated expression of the Fggy
gene in skeletal muscle during early differentiation and during neurogenic skeletal muscle atrophy
suggests that the increase in MyoD or myogenin may participate in the upregulation of Fggy
expression during muscle atrophy. Moreover, future investigation of the differential splicing of
Fggy during muscle cell development could determine if expression of specific MRF’s promotes
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expression of one isoform over another during muscle cell growth and differentiation. A better
understanding of the regulation of Fggy in muscle will help to improve our knowledge of the
functions that the different isoforms of Fggy play in muscle development and atrophy.
Fggy may function within the pentose phosphate pathway
The pentose phosphate pathway, also known as the phosphogluconcate pathway, generates
NADPH and molecules necessary for nucleotide synthesis (Alfarouk et al., 2020). While the liver
is found to have one of the highest levels of PPP activity (Heinrich et al., 1976), denervationinduced skeletal muscle atrophy causes an increase in levels of PPP activity specifically in muscle
cells (Wagner et al., 1977). This study linked the regeneration of skeletal muscle with enzymatic
activity of the PPP using a myotoxic local anesthetic called Marcaine that promotes rapid
regeneration of muscle tissue (Benoit and Belt, 1970). In humans, Fggy has been found to be
expressed highest in the liver (Fagerberg et al., 2014). This correlates with a previous study that
found Fggy may function as a D-ribulokinase in HEK293 cells, suggesting that the role of this
enzyme may be to phosphorylate free D-ribulose to prevent toxic accumulation (Singh et al.,
2017), as free D-ribulose is not found to be abundant in mammalian cells but is found in human
and rat urine (Futterman and Roe, 1955). It was also found that YDR109C, the yeast homolog of
Fggy, showed a substrate preference to D-ribulose (Singh et al., 2017). Interestingly, the Molecular
INTeraction (MINT) data base provides evidence of an interaction between Fggy and 6phosphogluconolactonase (Pgls) which, along with D-ribulose, has been identified as a component
of the pentose phosphate pathway (PPP). In the context of skeletal muscle atrophy, the previous
data suggests Fggy may play a role in the pentose phosphate pathway as the body attempts to
regenerate atrophied muscle tissue. As the PPP activity increases in muscle, the need to
phosphorylate D-ribulose for use in this pathway also increases, which could account for the
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increase in Fggy expression. This potential role for Fggy in skeletal muscle could be investigated
through the mutagenesis of regions predicted to interact with D-ribulose based on structural
homology models of the yeast Ydr109c and human FGGY proteins. It would be possible to
compare the amount of free ribulose in C 2C12 cells in response to ectopic expression of wild-type
and mutant Fggy, as well as, in response to Fggy expression knockdown. These studies could
determine if C2C12 cells contain enough free ribulose to be detected and if there are changes in
those levels in response to an increase or decrease in Fggy expression, as well as, if the kinase
activity of Fggy is necessary for ribulose phosphorylation. As it has not yet been determined which
mutation will result in a kinase dead Fggy protein, multiple mutations would have to be tested and
the amount of free ribulose measured in order to show the loss of activity. This could be done by
site-directed mutagenesis of conserved amino acids identified in 12 organisms across different
kingdoms of life (Fig. 21) (Singh et al, 2017) or through truncating the Fggy gene until a change
in activity is achieved, such as deletion of either the Fggy-N or Fggy-C functional domains which
are located at the N and C termini, respectively (Fig. 22).
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Figure 21. Alignment of D-ribulokinase protein sequences across different kingdoms of
life. Conserved amino acids are highlighted in increasingly darker shades of blue relative to a
higher degree of conservation. The top 20 specificity determining positions (SDPs) are highlighted
in red. The amino acids that are predicted to interact with the pentose substrate are highlighted
in yellow. This is based on structural homology models of the yeast Ydr109c and human FGGY
proteins (Singh et al., 2017).
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Figure 22. Model of the human Fggy protein. Shown in complex with the ligand d-xylulose
(light green color). The Fggy-C domain is highlighted in dark blue and Fggy-N domain is
highlighted in pink (Singh et al., 2017).
Fggy may interact with deubiquitinases
Although Fggy was found to be correlated with instances of sporadic amyotrophic lateral sclerosis
(S-ALS) (Dunckley et al., 2007), multiple other studies found no evidence to support this finding
(Daoud et al., 2012 and Cai et al., 2014). Interestingly, Fggy has been predicted to interact with
two deubiquitinases, Myb-like, SWIRM, and MPN domains-containing protein 1 (MYSMP1) and
Ubiquitin-specific protease 24 (USP24) (Jensen et al., 2008). MYSMP1 has been shown to act as
a transcriptional activator by releasing the inhibition caused by ubiquitination of histone 2A (H2A)
(Zhu et al., 2007). In addition, USP24 has been implicated in apoptosis and iron metabolism
responsible for avoiding cell death (Sun et al., 2018). USP24 has also been found to deubiquitinate
p53, which is necessary for the stabilization of p53 expression (Zhang et al., 2015). This is
interesting as USP24 is found to decrease 7 days after denervation in gastrocnemius muscle tissue
(Lang et al., 2017), while p53 is found to increase in expression 7 days after denervation in tibialis
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anterior muscle (Stouth et al., 2020). Skeletal muscle atrophy has been shown to cause an increase
in the expression of various deubiquitinases, which is thought to compensate for the increased
demand for ubiquitin that is needed to target proteins for degradation by the proteasome (Wing,
2013). Moreover, the removal of ubiquitin tags from some substrates may also disrupt normal
protein-protein interactions and complex formation and allow for ubiquitination of complexed
proteins by E3 ligases eventually leading to their destruction by the proteasome. Further
investigation into possible interactions between Fggy and USP24 and MYSMP1 through coimmunoprecipitation assays will provide a more complete understanding of the functional role of
Fggy in the molecular mechanisms of skeletal muscle atrophy. The finding that Fggy shows
increased expression under neurogenic atrophy inducing conditions is just one step to
understanding how skeletal muscle adapts to physiological changes.
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